GlassScriptPhysician profile
Mimi Joye Hilderley
NPI 1043905011
$1,707.65
in general payments reported to CMS, 2019-2025
24 companies · $972 in 2025
The $972 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $135 · 2024: $475 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.69 | 2022-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $165.02 | 2024-2025 | Farxiga, Calquence, Tagrisso |
| Kyowa Kirin, INC. | $125.71 | 2025 | |
| Phathom Pharmaceuticals, INC. | $123.27 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $67.24 | 2024-2025 | Enhertu, Injectafer |
| Axsome Therapeutics, INC. | $58.87 | 2025 | Auvelity |
| Tersera Therapeutics LLC | $56.71 | 2025 | Xermelo, Zoladex |
| Regeneron Healthcare Solutions, INC. | $48.84 | 2024-2025 | Libtayo |
| Myriad Genetic Laboratories, INC. | $43.89 | 2024-2025 | Myrisk |
| Lilly USA, LLC | $38.23 | 2024 | Zepbound |
| Exelixis INC. | $29.29 | 2025 | Cabometyx |
| Incyte Corporation | $28.91 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Abbvie INC. | $28.88 | 2024 | |
| Menarini Silicon Biosystems, INC. | $28.35 | 2025 | |
| Novartis Pharmaceuticals Corporation | $27.00 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $25.67 | 2024 | |
| Genmab U.S., INC. | $23.48 | 2025 | Epkinly |
| Adc Therapeutics America, INC. | $21.81 | 2025 | |
| Merck Sharp & Dohme LLC | $21.19 | 2025 | Keytruda, Welireg |
| Sobi, INC | $20.32 | 2024 | |
| Genzyme Corporation | $19.39 | 2025 | |
| Iovance Biotherapeutics, INC. | $17.32 | 2025 | Amtagvi |
| Deciphera Pharmaceuticals INC. | $15.69 | 2025 | Romvimza, Qinlock |
| Currax Pharmaceuticals LLC | $14.88 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Hilderley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.